SPOTLIGHT: Millennium chief gets lucrative deal

Deborah Dunsire's new job as CEO of Millennium came with a million-dollar payment to cover her unvested options in Novartis stock. She also pocketed a $300,000 signing bonus, an $800,000 annual salary, a bonus plan and options in Millennium stock. Story

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.